Takeda-Abbott Deal Reflects New Realities Facing Japanese Drug Makers
This article was originally published in PharmAsia News
Takeda's buyout of Abbott Laboratories' half of TAP Pharmaceutical Products reflects a new reality facing Japanese drug makers, according to an analysis. Japan's pharmaceutical business has been hampered by government efforts to lower health care spending at the same time population figures are declining. As a result, drug makers in the country are looking overseas for business expansion. Takeda has stepped up mergers and acquisitions abroad since last year, using the resources of foreign companies to supplant reduced business at home. (Click here for more - a subscription may be required
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.